Terafin

Quick links to important sections

Terafin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terafin

Property Description
Active Ingredient Terbinafine Hydrochloride
Form Tablet (Oral) and Topical Preparations (Cream, Gel, Solution/Spray)
Pharmacological Class Synthetic Allylamine Antifungal Agent
General Use Resolution of fungal infections
Origin Synthetic derivative (Naphthalene chemical family)

Terafin is a medication that contains the active ingredient Terbinafine Hydrochloride, which is classified as a highly effective Synthetic Allylamine Antifungal Agent. This classification indicates its targeted action against fungal pathogens. The compound is structurally related to naftifine, originating from the Naphthalene chemical family. The drug is broadly recognized for its fungicidal action, meaning it actively kills the fungal cells rather than merely inhibiting their growth. This pharmacological attribute means the medicine is designed to eliminate the root cause of the fungal disease, rather than just manage the symptoms. Pharmacological studies confirm that Terbinafine is known for its high lipophilicity, which allows it to accumulate effectively in tissues such as the skin and nails, a key differentiating factor that supports the treatment of persistent infections.

Composition, Forms, and General Use

Terafin is a single-ingredient product distinguished by its strategic formulations for both internal and external treatment. For systemic therapy, the drug is available as Tablets, intended for internal use against infections that are often resistant to topical approaches, such as those affecting the nail bed. For localized, superficial skin infections, the medicine is available as various topical preparations, including Cream, Gel, or Solution/Spray. Clinical assessments indicate its recognized efficacy against dermatophyte infections of the skin and nails. This dual-form composition ensures the active compound can be administered either orally for systemic diffusion or applied directly, providing a comprehensive strategy focused on eliminating the fungal pathogen.

What side effects are possible with Terafin?

Possible Side Effects and Safety Information

The safety profile of Terafin (Terbinafine) is defined by regulatory classifications of documented adverse reactions, categorized by frequency and the physiological systems affected. Reactions classified as Very Common (ge 1/10) include headache, certain gastrointestinal symptoms (such as diarrhea, dyspepsia, and nausea), rash, urticaria, and musculoskeletal pain (arthralgia, myalgia). Common effects (ge 1/100 to < 1/10) include depression, dizziness, and taste disturbance, which is officially termed dysgeusia and may involve complete loss of taste (ageusia).


The official documentation highlights the potential for Serious Adverse Reactions, which are categorized as rare events. These include severe liver injury, such as hepatic failure (sometimes requiring liver transplant or resulting in death), and life-threatening cutaneous reactions like Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and severe blood dyscrasias (e.g., neutropenia). The regulatory label notes that changes in taste and smell, which can be prolonged, have been reported to become permanent in some cases even after treatment is discontinued.

Safety Constraints

A key safety constraint documented in regulatory labeling is the contraindication for the oral formulation in individuals with pre-existing chronic or active hepatic disease. Furthermore, caution is advised for patients with renal impairment (creatinine clearance less than 50 mL/min). The drug is also associated with the potential precipitation and exacerbation of cutaneous and systemic lupus erythematosus, according to official regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that an overdose of this opioid-containing medicine is a life-threatening medical emergency requiring immediate professional intervention.


Documented Overdose Presentations

The most severe and life-threatening manifestation of an overdose is respiratory depression (slowed, shallow, or difficult breathing). Other critical signs include severe sleepiness, sedation, and not being able to respond or wake up (unresponsiveness).


Overdose Risks and Circumstances

  • Accidental ingestion of even one dose, particularly by a child, can result in a fatal overdose.
  • Crushing, chewing, or dissolving the extended-release tablet can lead to the rapid absorption of a potentially fatal dose.
  • The risk of overdose is increased in patients who are not opioid tolerant and by using higher-than-prescribed doses.

Required Emergency Action

Seek emergency medical help or call 911 immediately if any symptoms of severe respiratory distress or unresponsiveness are observed. Prompt medical attention is critical. Patients and caregivers should be prepared to discuss the availability and use of naloxone, a medication used to rapidly reverse the effects of an opioid overdose.

Therapeutic Uses of Terafin

This medication is commonly used to help with conditions characterized by fungal invasion, including Onychomycosis (nail fungus), Tinea Capitis (scalp ringworm), Tinea Pedis (athlete's foot), Tinea Cruris, and Tinea Corporis. These conditions often produce symptoms related to inflammatory or irritative states, such as intense itching (pruritus) and scaly rashes.

The treatment is relevant in clinical settings that involve conditions involving heightened symptoms of the nails and scalp, as well as acute manifestations on the skin. The benefit helps ease the overall symptom burden by supporting the patient during difficult episodes, especially in chronic manifestations like nail thickening and discoloration. It is also applied in scenarios where additional symptomatic support is needed for infections that can be resistant or disruptive during flare-ups. This support extends to high-risk patient groups, where symptomatic management assists with maintaining functional stability and is applied in addressing recurrent or episodic manifestations.


Quick Fact: Relief for Pruritus and Nail Discoloration

Regulatory References

  1. NIH MedlinePlus Drug Information on Terbinafine

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility requirements for oral Terafin (terbinafine) tablets, as documented in government regulatory sources, based on absolute contraindications and specific limitations.

Eligibility Scope

Classification Regulatory Status Affected Population
Contraindicated Absolute Prohibition Chronic or Active Hepatic Disease (Liver Disease), Known Hypersensitivity to Terbinafine.
Not Recommended Conditional Use/Limited Data Severe Renal Impairment (CrCl < 50 mL/min), Pregnancy, Breastfeeding Mothers, Children/Pediatric Population (use generally not established).
Caution Required Special Consideration Patients with pre-existing Psoriasis or Lupus Erythematosus, Older Adults (assess pre-existing organ function).

Official Eligibility Statements

Regulatory documents stipulate that Terafin is contraindicated in patients with active or chronic liver disease due to the risk of hepatotoxicity, and for any patient with a history of allergic reaction to the drug. Use is not recommended in patients with severely impaired kidney function, or in women who are pregnant or breastfeeding, as the drug is excreted into breast milk and clinical experience is limited or insufficient in these groups. Adults without these contraindications form the primary patient population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of oral Terbinafine Hydrochloride (Terafin) is primarily defined by its effects on drug metabolism, as documented in official regulatory sources.

Pharmacokinetic Interactions

Terafin is classified as a potent inhibitor of the CYP450 2D6 isozyme, which can lead to clinically significant increased exposure of co-administered medicines that are metabolized by this enzyme. For instance, co-administration with Desipramine resulted in a 5-fold increase in the drug's exposure (AUC).

Conversely, other medicines can alter Terbinafine's own clearance. Co-administration with the inducer Rifampicin has been shown to increase Terbinafine clearance by 100%, while the inhibitor Cimetidine decreased its clearance by 30%. Dual CYP inhibitors like Fluconazole also increase Terbinafine’s systemic levels.

Pharmacodynamic and Substance Interactions

Specific outcomes have been reported with certain medicines. Co-administration with the anticoagulant Warfarin has been associated with rare cases of changes in INR and/or prothrombin time. Rare cases of menstrual disturbance have also been reported with the concomitant use of Oral Contraceptives.

Concerning substances in food, Terbinafine has been documented to decrease the clearance of Caffeine by up to 21%.

Interaction-Related Restrictions

Use of Terafin is formally contraindicated in patients with chronic or active liver disease. This restriction reflects a heightened risk of adverse hepatic events and potential worsening of pharmacokinetic interactions in this population.

Mechanism of Action

The mechanism of Terafin (Terbinafine Hydrochloride) is a dual-action process that acts on the essential metabolism of fungal pathogens. It acts exclusively on the fungal organism, demonstrating high selectivity over human sterol biosynthesis enzymes.

Dual-Action Disruption of Fungal Cell Metabolism

This mechanistic domain centers on Terafin's function as a non-competitive inhibitor of the fungal enzyme Squalene Epoxidase ( SQLE). The inhibition of SQLE halts the Ergosterol biosynthesis pathway, which is critical for the fungal cell membrane's structure. This molecular interference initiates a destructive cascade leading to the cessation of fungal cellular functions.

Cellular Toxicity Through Squalene Accumulation

The cellular consequence of SQLE inhibition is a dual toxic mechanism that structurally destabilizes the fungal cell. The enzymatic block causes a critical deficiency of Ergosterol—the membrane's main building block—while simultaneously forcing the accumulation of Squalene inside the cell. The combined structural fragility and internal toxicity result in fungal cell death and the inactivation of the infectious organism.

Dosage and Administration Information

How Terafin is Used: Administration Guidelines

Terafin (Terbinafine Hydrochloride) is administered according to a structured protocol which differentiates use based on the infection site. The medicine is available for both oral systemic therapy and topical (dermal) localized treatment. The choice of route depends on the required depth of action against the fungal pathogen.

Standard Dosing and Administration

The standard dosing regimen for adult systemic use is 250 mg once daily. This frequency is maintained throughout the full prescribed course. For localized skin infections, the 1% topical preparations are typically applied once or twice daily.

Administration Detail Instruction Summary
Oral Tablets May be taken with or without food (meal-independent).
Oral Granules Must be taken mixed with a soft, non-acidic food; do not mix with fruit-based items.
Missed Dose Rule If a dose is missed, take it immediately; skip the dose if the next one is due in less than 4 hours.

Treatment Duration and Population Rules

Therapy duration is based on the infection site. Oral treatment for fingernail onychomycosis generally requires 6 weeks, while toenail onychomycosis requires 12 weeks of continuous daily administration. Topical courses typically range from 7 days to 4 weeks. In the pediatric population, oral dosing for Tinea Capitis is weight-based, with amounts varying from 125 mg to 250 mg daily, depending on the child’s body weight. Use is generally not recommended in patients with pre-existing hepatic or severe renal impairment (CrCl le 50 mL/min), a key constraint in the use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Terafin

Evidence for Systemic Treatment of Nail Fungus (Onychomycosis)

The primary body of research for the use of Terafin (Terbinafine) in fungal nail infections involves large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were used in research exploring how symptoms change over time, often comparing the oral tablet formulation against a placebo or other active control agents. Research examined outcomes related to the status of the fungus, known as Mycological Cure, which is verified by laboratory tests. They also monitored physical changes, described as Clinical Cure, such as the visual clearance of the nail.

Studies monitored patients for extended intervals, typically involving a treatment period followed by a long follow-up duration of up to 18 months. Findings describe patterns observed in the studies related to the outcomes measured for a composite of mycological and clinical clearance. Observed outcomes described the need for long follow-up periods to track the measured clearance due to the slow pace of nail growth.

Evidence for Treating Skin Infections (Tinea Corporis, Cruris, and Pedis)

Research for skin infections like Athlete’s Foot (Tinea Pedis) and Ringworm was evaluated in studies focusing on both the topical and oral forms of Terafin. Studies explored the use of the medicine in conditions presenting with cycles of stability and flare-ups, and were designed to measure the clearance of the fungus. The outcomes related to physical discomfort, such as intense pruritus (itching), scaling, and redness, were monitored. Research examined the oral formulation primarily in cases that were extensive or chronic, involving periods of heightened symptoms.

Research Gaps and Uncertainties

While the evidence base for Terafin is substantial, certain areas where research is still needed exist. Evidence quality varies across studies, especially for trials comparing different doses or shorter treatment schedules. Comparative evidence is lacking for the combination of oral and topical therapy versus oral therapy alone in many conditions. Subgroup findings are uncertain, particularly regarding the optimal use in patients with existing renal (kidney) or hepatic (liver) impairment. Studies contribute to the broader evidence landscape, but there is limited information for long-term outcomes and the pattern of resistance development across different regions.

Frequently Asked Questions (FAQ)

Common questions about Terafin (FAQ)


Q: How long does it usually take for Terafin to start working?

Studies and official information indicate that the active substance is rapidly absorbed into the bloodstream. However, because the medicine treats infections in slow-growing tissues like the nails, the visual improvement can take a longer time. For instance, studies have noted that the mean time until the full measured clearance for toenail infections was approximately 10 months after the treatment was completed.


Q: What happens if I miss a dose of Terafin?

Official guidance indicates that if a dose is missed, it is generally advised to take it immediately, unless the time for the next scheduled dose is near. Specifically, if the next dose is due in less than four hours, the missed dose should be skipped entirely, and the regular dosing schedule should be resumed.


Q: Is Terafin the same as [Name of similar-sounding drug]? What's the difference?

Terafin contains the active ingredient terbinafine hydrochloride. Official documents classify it as a synthetic allylamine antifungal agent. This classification refers to its unique chemical structure and specific method of action, which involves disrupting a process vital to the fungal cell membrane's structure.


Q: Why do some people say Terafin causes tiredness?

Tiredness, or fatigue, is not listed among the most common adverse reactions in the official documentation. However, post-marketing reports have noted that severe taste disturbance is a potential side effect. This has been reported to sometimes lead to decreased food intake and subsequent weight loss, which may be associated with feelings of tiredness or fatigue.


Q: Can I stop taking Terafin once my symptoms get better?

The treatment course for Terafin is defined by regulatory bodies and is fixed for different types of infections, such as a set duration of weeks for nail infections. The complete course is typically specified to achieve the measured clearance of the fungal infection. Therefore, complete resolution of physical signs may not happen until several months after the full treatment course has been finished.


Q: Is Terafin known to interact with common pain relievers like ibuprofen?

The official interaction documentation does not list specific non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as known interactions. However, official product information indicates that the medicine is classified as a potent inhibitor of the CYP2D6 enzyme, which can change how the body processes many co-administered medicines.


Q: Is there a generic version of Terafin available?

Yes, official drug approval records confirm that the active ingredient, Terbinafine Hydrochloride, is available as a generic medication in addition to the brand-name product.


Q: Is it okay to drink coffee while taking Terafin?

Official documents state that Terafin has been documented to decrease the clearance of Caffeine, the active substance in coffee, by up to 21%. While official documents do not list coffee as formally contraindicated, the potential for increased caffeine exposure is noted in the drug's profile.


Q: Are the side effects of Terafin permanent?

Most adverse reactions are temporary and are expected to resolve after the treatment is stopped. However, official labeling notes that changes in taste and smell (dysgeusia/ageusia) have been reported to become permanent in some rare cases, even after treatment has been discontinued.


Q: Does Terafin affect sleep patterns?

Sleep disturbance or insomnia is not listed among the very common or common adverse effects in regulatory documentation. However, post-marketing experience has included reports of changes in sleep patterns as a less common adverse effect.


Q: Does Terafin cause weight gain or loss?

Weight gain is not listed as a reported side effect in regulatory documents. Weight loss has been reported in post-marketing experience, generally as a result of severe taste disturbances that can reduce food intake.


Q: Why does the packaging say to be careful with sun exposure?

The official regulatory label advises that sun exposure, both natural and artificial (such as tanning beds), should be minimized while taking the tablets. This is because Terafin can make the skin more sensitive to light, a condition known as photosensitivity, which may lead to severe sunburn or other skin reactions.


Q: Is Terafin considered a 'strong' medicine?

Terafin is classified as a synthetic allylamine antifungal agent. Official documents describe its action as 'fungicidal,' which means it actively kills fungal cells, rather than simply inhibiting their growth. This mechanism is considered highly effective against dermatophytes.


Q: Does Terafin interact with common supplements like St. John's wort?

Regulatory guidance often states that there is not enough information to confirm the safety of combining Terafin with herbal remedies and supplements. This is because these products are generally not tested for their interaction effects on prescription medicines.


Q: Is there a liquid form of Terafin?

While the drug is most commonly available as tablets for systemic use and topical preparations for skin application, the official label also lists oral granules that can be mixed with soft, non-acidic food. An oral liquid form may also be available as a specially prepared compound in some instances.


Q: Are there any specific dietary restrictions while on Terafin?

For the Terafin tablets, there are no specific dietary restrictions, and they may be taken with or without food. However, the oral granule formulation must be mixed only with a soft, non-acidic food, and must not be mixed with fruit-based items.


Q: Does the effectiveness of Terafin change over time?

The drug is known for its effectiveness against fungal infections, but the research evidence section notes that the incidence of resistance development across different regions is an area where studies continue. The official evidence landscape is always evolving with new findings.


Q: Why is it restricted for people with certain mental health conditions?

The official documentation does not list specific mental health conditions as a formal contraindication. However, depression has been reported as a common side effect. The drug is also officially noted for its potential to exacerbate pre-existing cutaneous and systemic lupus erythematosus, a condition which can sometimes include psychiatric symptoms.


Q: Is Terafin safe to use before driving or operating machinery?

Common adverse reactions listed in the regulatory documents include dizziness. Therefore, the official documentation suggests caution regarding activities like driving or operating machinery.


Q: Can I use over-the-counter cold medicine while taking Terafin?

Terafin can affect the metabolism of many medicines, including some common cold preparations that contain substances like codeine or dextromethorphan. This is because the drug is classified as a potent inhibitor of the CYP450 2D6 enzyme, which metabolizes many co-administered medicines.


Q: What should I do if my symptoms don't improve after taking Terafin?

Clinical trials noted that full clearance of the infection can take several months after the complete treatment course is finished. The fixed duration of therapy is based on the infection site, and patients are typically monitored for outcomes related to the status of the fungus (Mycological Cure) after treatment is completed.


Q: Is Terafin a controlled substance?

No, according to official drug classifications in the United States, Terbinafine (the active ingredient in Terafin) is not classified as a controlled substance.


Q: Can I take vitamins or supplements while using Terafin?

Regulatory guidance often states that there is insufficient information to confirm the safety of combining Terafin with complementary medicines, herbal remedies, and supplements because they are generally not tested for their interaction effects on prescription medicines.


Q: What is the experience of people starting Terafin for the first time?

Official documents list headache, certain gastrointestinal symptoms (such as diarrhea, dyspepsia, and nausea), and rash as 'Very Common' adverse reactions. This indicates these effects are among the frequently reported experiences when starting the medicine.


Q: What is the most common reason people stop taking Terafin?

Official documentation lists common side effects like headache, GI issues, and temporary taste change, but does not specifically detail the primary reason or the exact rates at which patients discontinue the medicine.


Q: Can Terafin interact with birth control pills?

The Interactions section mentions that rare cases of menstrual disturbance have been reported with the concomitant use of oral contraceptives. This specific outcome is noted in the official drug profile.


Q: Is it true that Terafin has been on the market for a long time?

Official documents confirm that Terafin is an established medication with a substantial evidence base, which includes large-scale Randomized Controlled Trials and comprehensive meta-analyses. It is an agent whose use and efficacy against dermatophyte infections have been widely recognized and systematically reviewed.

How should Terafin be stored and disposed of?

How to Store and Dispose of Terafin?

The official storage conditions for Terafin require that the medication be kept in its original, tightly closed container at room temperature. To maintain stability and potency as defined in regulatory labeling, it must be stored in an area protected from excess heat and moisture.

  • Mandatory Storage: Store at controlled room temperature, typically between 15 C to 30 C (59 F to 86 F).
  • Protection: Keep the container tightly closed and shielded from light and moisture (e.g., do not store in a bathroom).
  • Handling: Ensure all medication is stored in a secure location, out of sight and reach of children and pets, to prevent accidental ingestion.

For disposal, the primary recommendation is to use a community drug take-back program or an authorized mail-back service. If these options are not readily available, most medicines not on the U.S. FDA's flush list can be disposed of in household trash by mixing the drug with an undesirable substance (such as used coffee grounds or cat litter), placing the mixture in a sealed bag or container, and discarding it. Official labeling instructs against flushing this medicine down the toilet unless specifically authorized.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terafin found in:

A-Z Index: